Clinical trials: Chemotherapy Induced Neuropathic Pain
- Condition Chemotherapy Induced Neuropathic Pain
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN)
Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Management of neuropathic pain associated with diabetic peripheral neuropathy, post-herpetic neuralgia, human immunodeficiency virus-related peripheral neuropathy, and chemotherapy induced peripheral neuropathy.
- Conditions
- Diabetic Peripheral Neuropathic Pain (DPN), Postherpetic Neuralgia (PHN), HIV-related Neuropathic Pain (HIV), Chemotherapy Induced Neuropathic Pain
- Trial name
- NCT00407511
- Testing
- Pregabalin
- Where
- 11 sites in Colombia, Ecuador and 3 more
- Volunteers
- 121 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain, Peripheral Neuropathy
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many chemotherapeutic agents including vincristine, paclitaxel, cisplatin, oxaliplatin, bortezomib and ixabepilone.
- Conditions
- Pain, Peripheral Neuropathy, Neuropathic Pain
- Trial name
- TTX-CINP-201 (NCT01655823)
- Testing
- Tetrodotoxin
- Where
- 23 sites in United States
- Volunteers
- 125 people
- Sponsor
- Wex Pharmaceuticals Inc.